Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2025 · 10-Q
Revenue$190.00K$190.00K— vs Q3 2024 Net Income-$25.74M-$25.74MN/M vs Q3 2024 EPS Diluted-$0.26-$0.26N/M vs Q3 2024 Operating Income-$26,745,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,513,000N/M Margins · derivedOperating margin-14076.3%
Net margin-13549.5%
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end